Protein misfolding underlies many neurodegenerative diseases, including the transmissible spongiform encephalopathies (prion diseases). Although cells typically recognize and process misfolded proteins, prion proteins evade protective measures by forming stable, self-replicating aggregates. However, coexpression of dominant-negative prion mutants can overcome aggregate accumulation and disease progression through currently unknown pathways. Here we determine the mechanisms by which two mutants of the Saccharomyces cerevisiae Sup35 protein cure the [PSI + ] prion. We show that both mutants incorporate into wild-type aggregates and alter their physical properties in different ways, diminishing either their assembly rate or their thermodynamic stability. Whereas wild-type aggregates are recalcitrant to cellular intervention, mixed aggregates are disassembled by the molecular chaperone Hsp104. Thus, rather than simply blocking misfolding, dominant-negative prion mutants target multiple events in aggregate biogenesis to enhance their susceptibility to endogenous quality-control pathways.
a r t i c l e s
Cellular phenotypes are established, in large part, by the collective activities of their unique proteomes, and alterations to the physical state of individual proteins, such as changes in conformation, have the capacity to induce marked phenotypic switches. The prototypical conformation-based phenotypes are those associated with prion proteins, which have been implicated in several distinct biological phenomena including transmissible neurodegenerative diseases in mammals, heritable traits in fungi and synaptic efficiency in an invertebrate 1 . These changes in cellular function, however, can only emerge if the misfolded prion proteins persist and are amplified to amounts that perturb normal cellular homeostasis. Accumulation of misfolded prion proteins is facilitated by their assembly into ordered aggregates, which not only protect these aberrant species from refolding or degradation but also template the conversion of other forms of the protein to a like state 1 . This conformational self-replication, along with the continuous fragmentation of aggregates into smaller complexes, mediates an exponential increase in misfolded prion protein over the course of disease 2 .
The efficient and autocatalytic pathway of prion protein misfolding provides a molecular explanation for the progressive nature of prion diseases, but it also complicates their effective treatment, which would require the complete resolution of existing aggregates. This challenge, however, may not be insurmountable. Naturally occurring polymorphisms in the mammalian prion protein PrP alter the pathological and clinical characteristics of prion diseases 1 . In most of these cases, heterozygosity at the PrP locus mitigates the severity of disease [3] [4] [5] [6] [7] [8] [9] . In addition, differences in prion protein sequence confer strain-dependent resistance to infection and to the transmission of disease between species [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , and coexpression of some allelic combinations reduces or eliminates the accumulation of misfolded PrP in vivo [22] [23] [24] [25] [26] . Intriguingly, the severity of these dominant-negative effects is dependent upon the relative stoichiometry of mutant and wild-type protein, and different mutants can be distinguished by the ratios at which they become effective inhibitors 23, 27, 28 .
Given the central role of misfolded prion protein in the appearance, maintenance and spread of prion-associated phenotypes, dominantnegative prion mutants are thought to inhibit the self-replicated misfolding of wild-type prion protein. In this scenario the observed ratio effects can be explained as differences in affinity, with the mutants inhibiting the conversion of wild-type prion protein to the misfolded form through direct binding 22, 27, 29 . However, distinct effective inhibitory ratios may also indicate that individual mutants interfere with prion propagation through unique pathways. For example, mutants that target the conversion step are predicted to act efficiently at substoichiometric levels given the limited number of templating surfaces on an aggregate, whereas mutants that alter fragmentation or transmission of aggregates may act only at higher concentrations where they incorporate into these complexes in amounts sufficient to alter their properties 30 .
Here we use the Sup35-[PSI + ] system of Saccharomyces cerevisiae to uncover the mechanisms by which dominant-negative prion mutants inhibit prion propagation in vivo. [PSI + ] is a self-replicating misfolded (prion) form of the translation release factor Sup35 (ref. 1). Under normal conditions Sup35 is synthesized and rapidly converted to the prion form in a [PSI + ] strain by interaction with and incorporation into existing aggregates 31 . The molecular chaperones Hsp104, Hsp70 (Ssa1) and Hsp40 (Sis1) must then fragment these aggregates, by extracting and unfolding constituent Sup35 monomers, to generate additional templates for conversion and to ensure their efficient transfer to daughter cells [32] [33] [34] [35] [36] [37] [38] . This misfolding partially compromises Sup35 function, leading to a defect in translation termination that can be easily scored in yeast strains encoding genes with nonsense mutations. For example, [PSI + ] strains carrying the ade1-14 allele form white colonies on rich and adenine-deficient media due to readthrough of a premature stop codon in the ADE1 open reading frame (ORF), but strains with defective prion propagation, or those that have lost the prion state ([psi − ]), form red colonies on rich medium and fail to grow in the absence of adenine as a result of the accumulation of active, non-prion state Sup35 (ref. 35) .
For these studies we focused on two dominant-negative prion mutants, the [PSI + ]-no-more (PNM) variants, Q24R and G58D (also known as PNM2) [39] [40] [41] . These substitutions map to two different elements in the bipartite Sup35 prion-determining domain, the glutamine-and asparagine-rich region (QNR, amino acids 1-40) and the oligopeptide-repeat region (OPR, amino acids 41-97), respectively, which are both necessary for the stable inheritance of the [PSI + ] prion 1 . Although both mutants dominantly induce prion curing, we show that they do so by targeting distinct events in the Sup35 misfolding pathway. In both cases, these changes impact aggregate dynamics in vivo, ultimately promoting chaperone-mediated disassembly of existing aggregates.
RESULTS

Effective inhibitory ratios distinguish PNM mutants
The dominant-negative effect of G58D on [PSI + ] propagation has been reported in some yeast strains but not others 40, 42 . These differences may reflect distinct interactions of the mutant with each genetic background, but the previous studies also differed in the expression level of the mutant relative to wild-type Sup35. To explore the possibility that PNM mutants inhibit prion propagation in a dose-dependent manner, we generated diploid [PSI + ] yeast strains expressing wildtype Sup35 at different ratios relative to the PNM mutants G58D and Q24R (2:1, 1:1, 1:2; see Supplementary Fig. 1 ). Expression of G58D at any ratio in a [PSI + ] strain eliminated growth on adenine-deficient medium, indicating reversal of the prion phenotype (Fig. 1a) . By colony color, the severity of this effect increased with G58D dosage, with a 1:2 ratio of wild type to mutant displaying a colony phenotype that was indistinguishable from the [psi − ] state (Fig. 1a) . The dominantnegative effect of Q24R expression on the [PSI + ] colony phenotype also increased with its dosage, but the prion colony color phenotype was suppressed even at the substoichiometric ratio (2:1 ratio of wild type to mutant; Fig. 1a ). (Fig. 1a,b) . However, [PSI + ] did not appear in wild-type meiotic progeny when G58D was expressed in excess of wild-type Sup35 in the parental diploid (1:2 ratio of wild type to mutant; 100% curing; Fig. 1b) , consistent with the complete reversal of the prion phenotype (Fig. 1a) . For Q24R, which had a more severe effect on the prion phenotype (Fig. 1a) , 30% of wild-type meiotic progeny lost [PSI + ] even at the substoichiometric ratio (2:1 ratio of wild type to mutant), and this instability increased with its dosage (Fig. 1b) . Thus, [PSI + ] curing in diploids expressing PNM mutants parallels the severity of the phenotypic reversal in these strains, and PNM mutants, like their mammalian counterparts, can be distinguished by their effective inhibitory ratios.
PNM mutants target multiple events in prion propagation
The distinct effective inhibitory ratios for G58D and Q24R may reflect differences in affinity for a single event in the Sup35 misfolding pathway or, alternatively, interference with different steps in this process. To distinguish between these possibilities, we first determined whether G58D or Q24R expression altered conversion of Sup35 to the prion form by analyzing their ability to incorporate into wild-type aggregates in vivo. In haploid strains, wild-type and PNM Sup35 did not interact in non-prion [psi − ] cells, as expected, but both the G58D and Q24R proteins were specifically co-immunoprecipitated with HA-tagged wild-type Sup35 in [PSI + ] cells (Fig. 2a) . Previous studies in vivo have demonstrated G58D aggregation in [PSI + ] strains 42 , but studies in vitro disagree on whether this variant can efficiently convert to the prion form 43, 44 . To assess the efficiency of G58D and Q24R conversion to the prion form in vivo, we monitored the appearance of stop codon read-through in zygotes formed by mating a [psi − ] strain expressing a fluorescent reporter of translation termination efficiency (GST-UGA-DsRed) to a [PSI + ] strain. Production of fluorescent protein reflects the quantitative and rapid incorporation of soluble Sup35 into aggregates and the concomitant reduction in its activity 31 . In a cross between G58D [psi − ] and wild-type [PSI + ] strains, the frequency of fluorescent zygotes was similar to a wild-type cross (~80% , Fig. 2b) ; however, the intensity of this fluorescence was ~20% lower in the mutant cross (Fig. 2c) , consistent with a previous study suggesting a mild conversion defect for G58D 43 . In contrast, we observed fluorescence in only ~40% of zygotes resulting from a cross between Q24R
[psi − ] and wild-type [PSI + ] strains, indicating a strong conversion defect for Q24R in vivo (Fig. 2b) . Next, we determined whether incorporation of PNM Sup35 into wild-type aggregates altered the efficiency with which they are fragmented in vivo. Because this process is altered by the thermodynamic stability of aggregates 45 , we assessed the sensitivity of these complexes, isolated from haploid strains expressing a 1:1 ratio of wild type to mutant (see Supplementary Fig. 2a,b) , to disruption with 2% (w/v) SDS at different temperatures 31 . Expression of G58D did not alter the fraction of total soluble Sup35 recovered at 50 °C, where aggregates remain intact (Fig. 2d) 31 . However, at both 60 °C and a r t i c l e s a r t i c l e s 70 °C, the amount of total soluble Sup35 increased by a factor of ~2.5 in comparison with a wild-type strain ( Fig. 2d) , indicating destabilization of the aggregates by G58D incorporation. For a strain expressing Q24R, a similar increase in total soluble Sup35 was detected at all temperatures in comparison with a wild-type strain (Fig. 2d) , implying that Q24R expression did not alter the thermodynamic stability of aggregates but rather led to the accumulation of soluble Sup35 in vivo. Thus, the different effective inhibitory ratios of the PNM mutants correspond to alterations of distinct events in the Sup35 misfolding pathway in vivo, with G58D primarily altering the fragmentation step and Q24R affecting the conversion step.
PNM mutants alter propagon accumulation but not transmission
Modulation of the rates of conversion and fragmentation correlate with differences in the size, number and transmissibility of aggregates in vivo, and thereby the stability of prion-associated phenotypes 46 .
To determine the mechanism(s) by which PNM mutants dominantly induce [PSI + ] loss, we assessed the effects of their expression on each of these parameters.
To determine the aggregate size distribution, we analyzed lysates of haploid strains expressing both wild-type and G58D or Q24R Sup35 mutants by semidenaturing detergent-agarose gel electrophoresis (SDD-AGE) 47 . For strains expressing either mutant, the size distribution of SDS-resistant aggregates was shifted to smaller complexes relative to wild-type strains (Fig. 3a) . This effect was more severe for Q24R, consistent with the enhanced frequency of prion loss (Fig. 1b) and increased accumulation of soluble Sup35 in strains expressing this mutant in comparison with G58D (Fig. 2d) . Similar effects were also observed in strains expressing a Q24K but not a Q24N or a Q24A allele (see Supplementary Fig. 2b-d) , suggesting that positive charge at this position mediated the dominant inhibition.
To determine if these changes in aggregate size correlated with the number of heritable prion units (propagons), we genetically determined these values for haploid strains expressing an extra copy of wild-type, Q24R or G58D SUP35 (see Supplementary Fig. 2a,b) using an in vivo dilution assay 48 . For the wild-type strain, the median number of propagons was ~100 (Fig. 3b) , and expression of Q24R and G58D had opposing effects on this baseline. For strains expressing Q24R, the median number of propagons decreased by a factor of ~7 (Fig. 3b) , consistent with both the decreased proportion of aggregated Sup35 (Fig. 2d) and the increased frequency of [PSI + ] loss (Fig. 1b) . In contrast, the median number of propagons increased by a factor of ~2 in the G58D strain relative to the wildtype strain (Fig. 3b) . This observation is consistent with the idea that G58D incorporation increases the efficiency of aggregate fragmentation, but it also indicates that the increased frequency of [PSI + ] loss in this strain (Fig. 1b) cannot be explained by a failure to generate sufficient propagons.
To determine if G58D induces prion curing by altering the efficiency of aggregate transmission, we used a fluorescence loss in photobleaching (FLIP) assay in strains expressing aggregates labeled with Sup35-green fluorescent protein (Sup35-GFP) 46 . For this analysis, we continually bleach either mother or daughter cells before cytokinesis, and monitor loss of fluorescence in the other cell as a proxy for protein transmission (see Supplementary Fig. 3 ). Using this assay, aggregates containing wild-type Sup35-GFP are transmitted with similar efficiencies in either direction in the presence or absence of G58D (Fig. 3c) , indicating that the dominant-negative effect of this mutant also does not result from a defect in aggregate transmission.
PNM mutants promote Hsp104-mediated disassembly of aggregates
The increase in propagons and the efficient transfer of aggregates to daughter cells are difficult to reconcile with an increased frequency of [PSI + ] loss for strains expressing G58D. However, we considered the possibility that the changes in aggregate accumulation and stability induced by PNM expression (Fig. 2d ) altered their interactions with other cellular components. We uncovered the molecular defects in prion propagation in haploid strains expressing both wild-type and PNM Sup35 (Figs. 2,3) , a mild overexpression of the prion protein relative to other cellular components. To determine if this imbalance impacted PNM effects, we assayed the number of propagons in diploid strains expressing either two copies of wild-type SUP35 or one copy each of wild-type and PNM SUP35 (see Supplementary  Fig. 4a ) to maintain proper expression ratios. Rather than inducing Ab: (Fig. 3b) , G58D expression in diploids resulted in a reduction in propagons by a factor of ~7.5 (Fig. 4a) . This enhanced inhibition of prion propagation in diploids was also apparent in a strain expressing Q24R, where the number of propagons decreased more markedly in the diploid than in the haploid strain relative to wild type (decrease by a factor of ~30 vs. ~7; Figs. 3b and 4a) . Together, the strong effects of dosage on propagon accumulation suggested that other cellular factors could be mediating the biological outcomes of PNM mutant expression.
The best-characterized trans-regulator of [PSI + ] propagation is the molecular chaperone Hsp104. To determine if imbalance between Sup35 and Hsp104 could explain the dosage effects on PNM efficacy, we constructed heterozygous disruptions of HSP104 in diploid strains expressing two copies of wild-type SUP35 or one copy each of wild-type and PNM SUP35 (see Supplementary Fig. 4a,b) to approximate our experiments in haploids. Disruption of a single copy of HSP104 decreased the number of propagons in a wild-type strain by a factor of ~1.5, consistent with its catalytic role in fragmentation (Fig. 4a) 32, 33 . In contrast, heterozygous disruption of HSP104 in strains expressing either G58D or Q24R increased the number of propagons by a factor of ~3-4 ( Fig. 4a) and partially reversed the phenotypic effects of PNM expression (Fig. 1a) , implying that an excess of Hsp104 activity mediated PNM inhibition of prion propagation in vivo. Because PNM expression did not alter Hsp104 protein levels (see Supplementary Fig. 4b,c) , we proposed that this increase in apparent Hsp104 activity arose because it was simply functioning as a better enzyme. Specifically, the Q24R conversion defect limits the production of aggregates (Fig. 2d) and thereby skews the substrateto-enzyme ratio, whereas the G58D-mediated decrease in aggregate stability (Fig. 2d) enhances fragmentation.
To experimentally determine the relationship between Hsp104 activity and PNM-dominant inhibition, we compared aggregate size, as a proxy for Hsp104-mediated fragmentation efficiency 45, 47 , with suppression of the [PSI + ] phenotype under various conditions. In a strain expressing a 2:1 ratio of wild type to G58D, heterozygous disruption of HSP104 (see Supplementary Fig. 4c ) decreased the mobility of aggregates by SDD-AGE (Fig. 4b, and see Supplementary Fig. 5a ), a r t i c l e s implying that Hsp104 activity was limiting, and this limitation suppressed the reversal of the [PSI + ] phenotype (Fig. 1a) . In contrast, heterozygous disruption of HSP104 in strains expressing a 2:1 ratio of wild type to Q24R or a 1:1 ratio of wild type to G58D led to the accumulation of both fast and slowly migrating aggregates (Fig. 4b , and see Supplementary Fig. 5b ), suggesting that Hsp104 activity was only partially limiting in these strains. Consistent with that idea, the heterozygous disruption of HSP104 only partially suppressed PNM effects on the [PSI + ] phenotype in these strains (Fig. 1a) and suppressed [PSI + ] loss in the G58D but not the Q24R-expressing strain (Fig. 1b) .
In a strain expressing a 1:1 ratio of wild type to Q24R, disruption of one copy of HSP104 failed to alter the migration of Q24R-containing aggregates (Fig. 4b, and see Supplementary Fig. 4c ), suggesting that Hsp104 activity remained in excess under these conditions, and, correspondingly, prion propagation remained inhibited (Fig. 1a,b) . Together, these correlations strongly suggest that Hsp104-mediated fragmentation is a crucial event in the dominant inhibition of prion propagation by PNM mutants in vivo. If this hypothesis is correct, prion propagation in PNM-expressing strains should be hypersensitive to excess Hsp104. To test this idea, we first determined the ratio of Sup35 and Hsp104 expression levels in [PSI + ] strains derived from two genetic backgrounds, 74-D694 and BSC783/4c, which differ in their sensitivities to G58D expression 40, 42 . In the more sensitive BSC783/4c strain, Hsp104 expression is elevated by a factor of ~2.5 relative to Sup35 in comparison with 74-D694 (Fig. 4c) , and the expression levels of the Hsp104 co-chaperones Ssa1 and Sis1 are also elevated in BSC783/4c (see Supplementary Fig. 6a,b) . Correspondingly, aggregates in BSC783/4c were shifted to faster migrating complexes by SDD-AGE (see Supplementary Fig. 6c) , consistent with the idea that increased sensitivity to PNM inhibition correlates with elevated fragmentation activity. To rule out the possibility that this hypersensitivity resulted from other genetic differences between the two strains, we overexpressed Hsp104 to various levels (see Supplementary  Fig. 4d ) in 74-D694 wild-type haploid strains that co-expressed either wild-type or PNM Sup35 (see Supplementary Fig. 2a,b) and determined the frequency of [PSI + ] loss. In a strain expressing wild-type Sup35, [PSI + ] loss was only observed when Hsp104 was overexpressed by factor of ~20 (2µ PGPD , Fig. 4d , and see Supplementary Fig. 4d ). In contrast, [PSI + ] loss was observed in both G58D-and Q24R-expressing strains with only a single extra copy of Hsp104 (cen P104 ), and these levels were elevated further upon overexpression of Hsp104 by a factor of ~5 and ~20 (2µ P104 and 2µ PGPD , Fig. 4d , and see Supplementary Fig. 4d) . Thus, increasing Hsp104 activity can elevate the sensitivity of a [PSI + ] strain to curing by PNM mutants.
Based on this link between the strength of PNM-dominant inhibition and Hsp104 activity, we proposed that PNM expression induces [PSI + ] curing by promoting the disassembly of aggregates in vivo. To monitor the fate of aggregated Sup35, we inhibited new protein synthesis by cycloheximide treatment and then determined the physical state of the existing protein at a later time point. In lysates prepared from a diploid strain expressing two wild-type copies of SUP35, the proportion of SDS-resistant Sup35 remained the same, indicating that previously aggregated protein remained in this fraction (Fig. 4e) . In contrast, ~50% of the previously aggregated protein, isolated from a strain expressing both wild-type and either G58D or Q24R Sup35, was resolubilized (Fig. 4e) , indicating that incorporation of PNM mutants promotes aggregate disassembly in vivo.
Because G58D and Q24R mediate their dominant-negative effects on [PSI + ] propagation by targeting distinct events, we reasoned that combining these mutations into a single polypeptide would create an even more potent inhibitor. Indeed, the colony color of a [PSI + ] haploid strain expressing a Q24R G58D double mutant was red in contrast with the pink color of colonies formed from strains expressing either single mutant (see Supplementary Fig. 2a,b) . Moreover, [PSI + ] was lost during mitotic division in a strain expressing a Q24R G58D double mutant at a greatly enhanced frequency relative to strains expressing either the Q24R (by a factor of ~6) or G58D (by a factor of ~85) single mutants ( Table 1) . Thus, endogenous quality control pathways can effectively compete with the process of [PSI + ] propagation if mild inhibitors targeting different events in the Sup35 misfolding pathway are combined.
DISCUSSION
Our studies indicate that the QNR and OPR regions make equally important but functionally distinct contributions to the efficient autocatalytic misfolding of Sup35 in vivo and therefore to the stability of the associated phenotype. Based on our analyses of the effects of Q24R and G58D expression, the QNR region is crucial for conversion to the prion form, whereas the OPR region determines the stability of aggregates and thereby their frangibility in vivo. Our observations are consistent with previous structural and genetic analyses of Sup35 (refs. 39,44,49-52). However, the PNM-induced alterations are mild (i.e., changed by a factor of ~2), implying that their dominant-negative effects cannot be explained simply by the failure to replicate the misfolded species. Instead, these mutations exert their effects on a cellular level by promoting the chaperone-mediated disassembly of aggregates through different pathways: by lowering the substrate-to-enzyme ratio in the case of Q24R or by enhancing fragmentation efficiency in the case of G58D. Although overexpression of Hsp104 was originally thought to induce aggregate disassembly, biochemical and genetic evidence is mounting that the excessive level of Hsp104 required to cure wild-type [PSI + ] strains is likely to act through an unknown pathway and not through an elevated rate of fragmentation 47, 53, 54 . Thus, our studies are the first to our knowledge to demonstrate that existing aggregates can be directly and efficiently resolved by endogenous chaperones.
By uncovering the mechanism of prion curing by G58D expression, we have resolved existing conundrums in the field. First, the discrepancy in G58D effectiveness according to genetic background 40, 42 can be explained by differences in levels of Hsp104, Hsp70 and Hsp40. Second, the dominant-negative effects of G58D expression had been previously reported to be conformation-specific: whereas G58D expression cured the Sup35 "strong" conformation ( 42 .
Intriguingly, the correlation between effective inhibitory ratio and mechanism of interference for the PNM mutants may also hold for a r t i c l e s at least two dominant-negative PrP mutants. In vitro, the dominantnegative hamster PrP Q172R mutant appears to function analogously to Sup35 Q24R, converting to the prion form inefficiently and inhibiting conformational self-replication at a substoichiometric level 27, 55 . In contrast, the dominant-negative hamster PrP Q219K mutant behaves with striking similarity to Sup35 G58D. PrP Q219K is efficiently incorporated into aggregates 27, 29, 56 , but this incorporation alters the physical properties of these complexes, lowering their sensitivity to proteolysis 29 . Consistent with the behavior of Sup35 G58D, PrP Q219K effectively inhibits prion propagation only when present in excess to wild-type PrP in vitro 27 , implying that this mutant impacts the frangibility of aggregates in vivo. Indeed, Q219K, like G58D, exhibits conformation-specific inhibition of prion propagation in vivo, acting as a dominant negative toward the less thermodynamically stable Ch/RML variant but not the more thermodynamically stable 22L variant 28, 57 . These remarkable parallels between the two systems suggest that the pathways mediating prion curing by PNM mutants in yeast may provide a new framework for revealing mechanistic insight into the dominant inhibition of prion propagation in mammals. Together, our studies suggest that the interplay between the sequence, conformation and cellular environment of a prion protein combine to determine the balance between the assembly and disassembly of aggregates, and thereby the stability of the associated phenotypes. Thus, it is not simply the physical attributes of aggregates that normally preclude their resolution but instead their assembly pathway, which is too efficient to allow ongoing disassembly events to effectively compete. Our observations indicate that this balance can be reversed by mild disruption of either the conversion or the fragmentation step of the misfolding pathway in vivo. Although attempts to cure established prion infections with externally delivered dominant-negative PrP mutants have yet to succeed in animals [24] [25] [26] , our observations of prion curing in the yeast system indicate that the combination of functionally distinct mutations or the expression of dominant-negative mutants in cells with altered chaperone levels lead to the potent inhibition of prion propagation in vivo. Thus, a system-based approach to prion intervention represents a potentially promising direction in which to explore future therapies.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. 
